Loading...
Loading...
Acceleron Pharma Inc.
XLRN today announced that it has priced an underwritten public offering of
3,750,000 shares of common stock at a price to the public of $40.00 per
share for gross proceeds of $150 million. In connection with this
offering, Acceleron has granted the underwriters a 30-day option to
purchase up to an additional 562,500 shares of common stock.
Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are acting
as joint book-running managers for the offering. JMP Securities is
acting as the lead manager and FBR is acting as co-manager for the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in